A Phase I Clinical Study to Investigate the Safety and Tolerance of Therapeutic Bacillus Calmette-Guerin( BCG) in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
Latest Information Update: 10 Apr 2024
At a glance
- Drugs BCG bladder cancer thrapeutic Chengdu CoenBiotech (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chengdu CoenBiotech
- 10 Apr 2024 New trial record